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Abstract Excision repair cross complementation group 1
(ERCC1) is a key component of homologous recombination-
based repair of interstrand DNA cross-links (ICLs). As a con-
sequence, ERCC1 mediates resistance to mitomycin C (MMC)
and platinum chemotherapeutic agents and may predict treat-
ment failure. Clinical response to MMC or cisplatin (CDDP)-
based radiochemotherapy (RCT) was assessed in 106 head and
neck squamous cell carcinoma (HNSCC) patients and correlat-
edwith cell nuclear immunoreactivity of themousemonoclonal
(clone: 8 F1) ERCC1 antibody in tumor tissue samples. BEAS-
2B epithelial and Detroit 562 pharyngeal squamous carcinoma
cells were treated with CDDP,MMC, and 5-fluorouracil (5-FU)
at 50 % growth inhibitory (IC-50) concentrations. ERCC1
protein synthesis was compared with cell cycle distribution
using combined immunocytochemistry and flow cytometry.
ERCC1 messenger RNA (mRNA) and protein expression
was investigated in normoxic and hypoxic conditions in Detroit
562 cells. Clinically, the nonresponder revealed significantly
lower HNSCC tissue ERCC1 immunoreactivity than the re-
sponder (p=0.0064) or control normal mucosa, which led to
further mechanistic investigations. In vitro, control cells and
cells treated with cytotoxic agents showed increasing ERCC1
levels from the G1 through S and G2 phases of the cell cycle. In
CDDP-treated cells, ERCC1 mRNA and protein expression
increased. Under hypoxic conditions, ERCC1 gene expression
significantly decreased. Although ERCC1+ cells show in-
creased chemoresistance, they might be particularly radiosen-
sitive, representing G2 cell cycle phase and less hypoxic.
ERCC1 expression might be indirectly related with some con-
ditions important for RCT treatment, but it is not a clear
predictor for its failure in HNSCC patients.
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Introduction
The Xeroderma pigmentosum group F protein (XPF) and
excision repair cross complementation group 1 (ERCC1) exist
as a heterodimer, which is a structure-specific nuclease nec-
essary for the repair of interstrand DNA cross-links (ICLs) [1].
Environmental carcinogens contained in air pollution, such as
polycyclic aromatic hydrocarbons, aromatic amines, or N-
nitroso compounds, predominantly form DNA adducts and
also generate ICLs [2]. ICLs are an extremely toxic class of
DNA damage incurred also during cancer chemotherapy.
They covalently tether both strands of duplex DNA,
preventing the strand unwinding that is essential for polymer-
ase access. In consequence, ICLs induce double strand break
(DSB) formation during cell cycle progression into S phase.
Previously published evidence demonstrated that ERCC1 is
required for the resolution of cross-link-induced DSB, which
leads to the subsequent repair of cytotoxic intermediates by
homologous recombination [3]. ERCC1-deficient mice show
severe growth retardation associated with premature replica-
tive senescence leading to liver failure and death at 4 weeks of
age [4]. ERCC1 knocked down cells were delayed in their cell
cycle and became multinucleated. These data have suggested
that ERCC1 might also play a role in mitotic progression,
which may be critical during development [5]. The ERCC1/
XPF complex has been proposed to play a role in mitotic
recombination as well as in nucleotide exchange repair [4].
If cells that cannot repair their damaged DNA proceed through
either replication or binucleation (which involves a round of
replication followed by an acytokinetic cell division), this
could lead to the fixation of mutations and the creation of
chromosomal aberrations [4].
Current data on the prognostic and predictive value of
ERCC1 tumor immunoreactivity are inconsistent. A previous
study has reported that low ERCC1 expression is associated
with genomic instability and higher risk of cancer [6, 7].
Increased genetic instability was related with increased
recurrence risk [8] and worse long-term outcome of head
and neck squamous cell carcinoma (HNSCC). In fact,
chemotherapeutic agents such as cisplatin, cis-dichloro-
diamine-platinum (CDDP) also induce ICLs, and apparent-
ly, high immunohistochemical detection of ERCC1 might
be associated with CDDP resistance. Referring to a previ-
ous study, patients with low expression of ERCC1 had
significantly higher 3-year progression-free and overall sur-
vival rates [9]. In accordance, patients with low ERCC1
expression are more likely to benefit from CDDP induction
chemotherapy than patients with high ERCC1 expression
[10, 11]. In contrast, Koh et al. reported that ERCC1 tumor
immunoreactivity had no effect on chemotherapy response
in patients with oropharyngeal, hypopharyngeal, and laryn-
geal cancer treated with CDDP containing induction che-
motherapy [12]. Moreover, De Castro et al. recently report-
ed that high ERCC1 expression seems to be associated
with better overall survival rates in HNSCC patients sub-
mitted to adjuvant cisplatin-based chemoradiation [13].
Confirming these data, studies done in two other tobacco-
related cancers, namely nonsmall cell lung cancer and
pancreatic adenocarcinoma, treated by surgery alone, sug-
gest that ERCC1 positivity may implicate a favorable prog-
nosis [14]. In a recent publication, Bisof and coworkers
mentioned that studies on the association of ERCC1 ex-
pression and survival in head and neck carcinoma patients
treated with definitive or adjuvant radiation therapy yielded
conflicting results [15]. In fact, Bisof and coauthors have
published that ERCC1 expression had no impact on overall
survival in head and neck carcinoma patients treated with
definitive radiotherapy (DR) or adjuvant radiotherapy (AR)
[15]. Similarly, Johung and coauthors published that
ERCC1 expression did not predict radiotherapy resistance
in laryngeal cancer [16]. In all these studies, ERCC1 gene
expression was assessed employing immunohistochemistry
with the same antibody clone (8 F1).
Pretreatment immunohistochemical analysis of ERCC1
protein representation in formalin-fixed paraffin-embedded
(FFPE) tumor biopsies obtained during diagnostic endoscopy
was established at our department on a weekly routine basis.
Similar to the results of De Castro et al. [13], we found a
positive relation between complete response after primary
concomitant radiochemotherapy (RCT) (5-fluorouracil (5-
FU)/mitomycin C (MMC) or 5-FU/CDDP) and high repre-
sentation of ERCC1 in tumor cell nuclei. Since there was no
mechanistic explanation for this result, we initiated some
in vitro investigations. In detail, we compared two ERCC1
antibodies in relation to XPF expression and examined
ERCC1 expression in vitro under normoxic and hypoxic
conditions in response to MMC and CDDP in relation to cell
cycle phases.
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Materials and methods
Patient characteristics
The procedures followed were in accordance with the ethical
standards of the committee on human experimentation of the
institution or in accord with the Helsinki Declaration of 1975
as revised in 1983. Permission was obtained from the local
ethics committee to collect pretreatment biopsy samples for
paraffin embedding, sectioning, and immunohistochemical
analysis (Reference Number: UN4428 303/4.14). Patients
with locally advanced unresectable squamous cell carcinomas
of the head and neck region treated between April 2008 and
October 2013 with primary RCT at the Department of Otorhi-
nolaryngology—Head and Neck Surgery, Medical University
Innsbruck, were consecutively included. Pretreatment tumor
samples were obtained during diagnostic panendoscopy. Tu-
mor biopsies were immunohistochemically stained with the
ERCC1 antibody 8 F1 from Acris (Herford, Germany). The
proportion of ERCC1+ cells and nuclei in tumor cell nests was
counted in 10 high power fields. All patients received primary
RCT. Treatment response was assessed 6–8 weeks after the
end of treatment and grouped into either complete response or
treatment failure, because incomplete responses were associ-
ated with poor survival. Clinical data are summarized in
Supplementary Table 1. Twenty-six normal mucosa tissue
specimens were derived from uvulopalatopharyngoplasties
(UPPP) and other nontumor samples.
Treatment and clinical evaluation of treatment response
Patients underwent treatment upon multidisciplinary tumor
board recommendation. The standard treatment for advanced
HNSCC not suited for surgical treatment was primary radio-
chemotherapy (pRCT). Standard pRCT consisted of percuta-
neous normofractionated computer tomography CT-supported
3D-planned radiotherapy (RT) with 70–72 Gy, combined with
CDDP or mitomycin C and 5-fluorouracil according to com-
mon protocols [17–19]. In patients not eligible for chemother-
apy, RT with concomitant weekly cetuximab or—in case of
cetuximab intolerance—a hyperfractionated RT protocol was
administered [20, 21] (detailed in Supplementary Table 1). A
complete diagnostic workup including biopsies from the ini-
tial tumor regions was performed 8 to 12 weeks following end
of treatment. Moreover, normal mucosa samples of 26
nontumor patients were included. With regard to the study
aim, these patients had no relevant mucosal abnormalities.
ERCC1 immunohistochemistry
Five-micrometer-thick paraffin sections were dewaxed and
antigen retrieval was performed in a DiscoveryTM automated
staining system (Ventana, Tucson, AZ, USA). ERCC1
antibodies were added to the sections by manual titration
(mouse monoclonal clone 8 F1 Acris, 1:100 dilution), and
the staining was completed by the DiscoveryTM automated
staining system using universal secondary antibody solution,
hematoxylin counterstaining, and the DAB MAP Kit (all
Ventana products). All sections were stained with control
mouse and rabbit immunoglobulins, using the same highest
concentration as for the primary antibodies, and these controls
were not reactive [22]. The immunohistochemical reactions
were observed independently by two blinded observers, who
collected 10 representative tumor cell nests from each speci-
men [22], or 10 random areas of normal mucosa (UPPP
samples). These regions were analyzed on an Olympus
BX50 microscope (Tokyo, Japan) and on the TissueFaxs
system (Tissuegnostic, Vienna, Austria). The whole number
of cells and the number of immunopositive cells were counted
in 10 high power fields (HPF). The staining index (percent of
positive cells) was calculated as the average ratio between the
positive cells and whole cell number [22]. Correspondingly,
the nuclear staining index was calculated for cell nuclei only.
Comparison of the immunohistochemical reaction of 8 F1
and FL-297 ERCC1 antibodies and of a XPF antibody
on a random sample of patients
Paraffin sections of 18 HNSCC specimens (Supplementary
Table 2) were used to compare the immunohistochemical
reactivity of two ERCC1 antibodies: mouse monoclonal,
clone 8 F1 from Acris (1:100 dilution), and rabbit polyclonal,
FL-297 from Santa Cruz Biotechnology (Santa Cruz, CA,
USA, 1:250 dilution) as previously described and suggested
by Niedernhofer and coworkers [23–25]. For immunohisto-
chemistry of XPF, the mouse monoclonal antibody SPM228
(1:1,000; Abcam, Cambridge, MA) was used [26].
ERCC1 gene expression under normoxic and hypoxic cell
culture conditions
BEAS-2B immortalized noncancer bronchial epithelial cells
[27] and Detroit 562 metastatic pharyngeal squamous cell
carcinoma cells were used [28]. Both cell lines were of com-
mercial origin, and their culture conditions have been pub-
lished before [28]. In some western blot experiments, SCC-25
oral squamous cell carcinoma cells were used.
Hypoxic cell culture conditions were performed in a
Memmert INCO 108 incubator (Schwabach, Germany),
which provides controlled 1 % O2. Detroit 562 cells were
plated at 5×104/ml in six-well plates at 3 ml/well. After an
initial 48-h culture period, one plate was used as “control
zero” for RNA isolation and real-time PCR. The further plates
were used for RNA isolation and protein fractionation in three
repeats. Cells were cultured after the initial 48-h normoxic
culture for 48–96 h normoxic, or for 48–72 h in hypoxic
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conditions, and also combined, 48 h hypoxic followed by 24
or 48 h normoxic conditions. These culture conditions were
based on a published reference [29]. Gene expression of
ERCC1 was analyzed related to the “control zero” condition.
For protein synthesis analysis, cells were plated at 5×104/
ml in six-well plates (3 ml cell suspension/well), grown for
4 days, and on the fifth day, cells in one well were scraped into
500 μl extraction buffer followed by nonnuclear and 0.35 M
NaCl nuclear protein fractionation as described previously
[30]. Also, cells in hypoxic or normoxic or combined culture
were used for nuclear protein fractionation. Nuclear and non-
nuclear protein fractions were subjected to protein concentra-
tion measurement, and 10 μg proteins were used for western
blots with antibodies of SPM228 (XPF, in 1:1,000 dilution),
8 F1 (ERCC1, mouse monoclonal, in 1:250 dilution), and FL-
297 (ERCC1, rabbit polyclonal, in 1:200 dilution). Blots were
processed in a western blot protocol previously detailed [31].
ERCC1 gene expression under chemotherapy (IC-50 dose)
BEAS-2B and Detroit 562 cells were plated at 5×104/ml in
96-well plates, 100 μl/well, were cultured for 48 h, and were
treated with 0.1–100 μmol/l CDDP [32] or MMC [33] or 5-
FU [34] for 48 h in complete medium (with medium replace-
ment after 24 h), according to previous publications [33–35].
After 48 h of treatment, the medium was replaced with a fresh
one, and after 24 h, the (3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazoliumbromide (MTT) assay was performed as
described previously [35]. The formazan crystals were dis-
solved in 10 % sodium dodecyl sulfate- and 10 mM HCl-
containing solution, and the absorption was measured at
550 nm using an Anthos 2010 ELISA reader (Salzburg,
Austria). The absorption values of cell-free blank wells were
removed from the absorption values of cell-containing wells,
and the average absorption value of untreated cells was con-
sidered as 100 % growth capacity. The absorption values of
the treated cells were related to the controls as percentage of
growth capacity. The relationship between growth capacity
and treatment drug concentrations was analyzed by regression
using nonlinear dose-response fitting methods of GraphPad
Prism 4.03 (GraphPad Software Inc, San Diego, CA, USA),
and concentrations were determined, which cause 50 %
growth inhibition compared to untreated cells (IC-50).
ERCC1 gene expression at the messenger RNA (mRNA)
level has been determined after treatment with IC-50 doses of
CDDP, MMC, and 5-FU. BEAS-2B and Detroit 562 cells
were plated at 5×104/ml in 10 cm cell culture dishes, 10 ml/
dish, and were then cultured and treated as described by the
IC-50 determination with IC-50 concentrations of CDDP or
MMC or 5-FU for 48 h in complete medium (with medium
replacement after 24 h). After 48 h of treatment, the medium
was replaced with a fresh one, and after 24 h of culture in
complete medium, the cells were used for immunocytometry
[36] or for RNA isolation [37–39]. For RNA isolation, the
same cells and treatments were performed as for
immunocytometry. RNAwas reverse-transcribed as published
before [31, 38], and gene expression levels of ERCC1 were
determined according to previous reports [31, 38–40]. All
used human PCR primers were published previously: ERCC1
[41]; β-actin [42], which was used as a housekeeping gene,
was not regulated in control and treated samples and also not
in hypoxic cultures. The relative gene expression was calcu-
lated as previously reported [42].
Cell cycle dependence of ERCC1 protein synthesis
After the above-detailed cell culture and treatments, cells were
trypsinized and suspended in 750 μl ice-cold phosphate buff-
ered saline (PBS)/MgCl2 (PBS containing 2 mMMgCl2) / 10
6
cells, and 250 μl cold 1 % BD-Cellfix (Becton Dickinson,
Vienna, Austria) was added under continuous vortexing [36].
This mixture was incubated on ice for 1 h, and the cells were
centrifuged at 1,200 rpm for 5 min at 4 °C, followed by 15min
incubation in 0.2 % Tween-20/PBS/106 cells at 37 °C. The
cells were centrifuged at 1,200 rpm for 5 min at 4 °C again and
then incubated in 5 % bovine serum albumin in PBS/MgCl2 at
room temperature for 20 min followed by centrifugation at
1,200 rpm for 5 min at 4 °C. The cells were resuspended in
1 % bovine serum albumin in PBS/MgCl2 and were incubated
either with isotype-specific control mouse IgG2b, or with
ERCC1 (8 F1, Acris) antibody at 100 times dilution at room
temperature for 90 min followed by centrifugation at
1,200 rpm for 5 min at 4 °C. The immunocytochemical
reaction was detected by 100 times diluted anti-mouse Alexa
488 (Jackson ImmunoResearch, Newmarket, Suffolk, UK)
incubated in 1 % bovine serum albumin in PBS/MgCl2 at
room temperature for 30 min. Subsequently, DNAwas stained
with propidium iodide for cell cycle analysis as published
before [35]. The double-stained cells were flow cytometrically
examined on a Coulter Epics XL-MCL (Beckman Coulter,
Brea, CA, USA). In addition to the cells that reacted through
the whole procedure, the following controls were used for
setting up the flow cytometry conditions and for compensa-
tion: cells reacted with whole antibodies but without
propidium iodide and anti-mouse Alexa 488, cells
immunoreacted with isotype-specific control mouse IgG2b
and DNA-stained with propidium iodide, and cells reacted
with ERCC1 (8 F1, Acris) antibody but DNA not stained with
propidium iodide. Frequency diagrams (histograms; fluores-
cence intensity on the X-axis, events on the Y-axis, or fluores-
cence intensity on the X-axis, events related to all events on
the Y-axis) and scattergrams were recorded for Alexa 488 at
the fluorescence-1 (FL-1), and for propidium iodide at the
fluorescence-1 (FL-3) channel of a Beckman Coulter XL-
MCL. Doublets and adhered cells were removed from the
DNA analysis using FL3 signal height/signal area graphs.
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Statistical analysis
Each experiment was performed in four independent sets
containing four biological repeats/set. The raw experimental
results were tested for normal distribution by D’Agostino and
Pearson omnibus normality test using the GraphPad Prism
4.03 (GraphPad Software Inc, San Diego, CA, USA). Average
values were compared by nonparametric tests (Mann-
Whitney) or by Student’s t tests depending on the distribution
of the data. Logistic analysis was performed using MedCalc
12.4 (Ostend, Belgium). Correlation analysis of the staining
index of ERCC1 and XPF antibodies was performed by the
“Pearson r” method using GraphPad Prism 4.03.
Results
Low ERCC1 expression was associated with treatment failure
after primary RCT
During the study period, 106 patients with unresectable
HNSCC treated with primary concomitant RCT were in-
cluded. Of these, 68 responded completely, while 38 failed.
Tissue samples of 26 patients without tumor containing
normal mucosa served as controls. ERCC1 staining indices
between these three groups differed significantly (p<0.01).
Particularly, tumor specimens of treatment failures revealed
significantly lower ERCC1 expression (staining index 28±
30 %; mean±SD) than specimens from controls (58±40 %;
p=0.0064), while specimens from treatment responders (48
±35 %) did not (p>0.05) (Fig. 1). Taking different sites of
HNSCC into consideration, this tendency has been seen in
the oral cavity, oropharynx, hypopharynx, and larynx, but
the highest difference between therapy responder and non-
responder patients was found in the hypopharynx (Supple-
mentary Material 3).
These results did not comply with some recent publications
suggesting an association of treatment failures with high
ERCC1 expression [10, 11]. This brought us to reevaluate
the role of ERCC1 on a mechanistic level. In the first step, we
wanted to rule out that simple unspecificity of the antibody
clone 8 F1 might bias these results [23, 24, 26].
Comparison of 8 F1 and FL-297 ERCC1 antibodies
Recently, the specificity of the most frequently used
ERCC1 antibody clone 8 F1 was doubted by Niedernhofer
and coworkers and another ERCC1 antibody, FL-297, was
favored [23, 24, 43]. In a random sample of 18 tumor
specimens, we compared the immunohistochemical reaction
products to 8 F1 (ERCC1), FL-297 (ERCC1), and to the
XPF antibody SPM228, the partner of ERCC1 in dimer
formation. For ERCC1 as a DNA excision repair enzyme,
nuclear presentation was expected. The 8 F1 antibody
revealed relative homogenous cell nuclear staining in
HNSCC specimens (Fig. 2a, arrows), while heterogeneous
perinuclear staining and cytoplasmic reactions were ob-
served with the FL-297 antibody (Fig. 2b, arrows). The
SPM228 antibody homogenously stained the cell nuclei
(Fig. 2c, arrows).
Nuclear staining indices for 8 F1 (ERCC1) and
SPM228 (XPF) correlated significantly (r=0.51; p=0.021)
(Table 1, Supplementary File 4), while not for SPM228
and FL-297 (r=0.031; p=0.904). Moreover, the ERCC1
staining with FL-297 and 8 F1 did not correlate (r=0.159;
p=0.53) (Table 1, Supplementary File 4).
Taken together, ERCC1 detected by the 8 F1 antibody
clone revealed the expected nuclear representation and
correlated with its functional partner XPF, while polyclon-
al FL-297 localized perinuclear and cytoplasmic and its
staining distribution did not correlate with that of XPF.
We interpret these data that the required immunohisto-
chemical specificity of the 8 F1 clone for ERCC1 detec-
tion is sufficient and that the unexpected low ERCC1
expression in HNSCC treatment failures was not due to
unspecific staining of the antibody employed. This conclu-
sion was supported by western blot investigations in cell
lines (see below).
Fig. 1 Twenty-six normal mucosa samples and 106 HNSCC tumor
tissue samples have been stained with 8 F1 ERCC1 antibody, and the
percentage of stained cells in tumor cell nests or in high power fields of
normal mucosa has been evaluated. There was no significant difference
between the staining representation of normal mucosa and therapy re-
sponder HNSCC, but the therapy nonresponder HNSCC patients have
shown significantly lower (p=0.0064) ERCC1 representation compared
to the normal mucosa and responder patients
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Specificity of the 8 F1 antibody clone in squamous cell
carcinoma cell lines
For western blot analyses, oral SCC-25 [38] and pharyngeal
Detroit 562 [44] squamous cell carcinoma cells and noncancer
virally immortalized bronchial epithelial BEAS-2B cells [27]
were employed. ERCC1 gene expression was assessed using
real-time RT-PCR. In all of the investigated cells, significant
ERCC1 gene expression was detected with Ct values of 25–
28.
Cell nuclear (histone-free) and cytoplasm extracts were





analysis of ERCC1 using
antibodies 8 F1 (a) and FL-297
(b) and of XPF using SPM228 (c)
in serial sections of nasopharynx
squamous cell carcinoma. The
8 F1 ERCC1 and the SPM228
XPF antibodies show cell nuclear
reaction in comparable areas of
serial sections, while the FL-297
ERCC1 antibody shows mainly
perinuclear and cytoplasmic
reaction in comparable areas of
serial sections. The reaction of
FL-297 antibody is more
extended than the one of the other
two, which fit each other. Bars=
50 μm





Distribution of the data
on the X- and Y-axes
Pearson r p value Represented Comment
8 F1 (ERCC1) FL-297 (ERCC1) Normal distribution 0.159 0.5276 Supplementary File 4 No correlation
8 F1 (ERCC1) SPM228 (XPF) Normal distribution 0.510 0.021 Supplementary File 4 Significant correlation
FL-297 (ERCC1) SPM228 (XPF) Normal distribution 0.031 0.904 Supplementary File 4 No correlation
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western blot analyses. ERCC1 was expected at 37 kDa and
XPF at approximately 116 kDa [25]. The rabbit polyclonal
FL-297 antibody raised against ERCC1 recognized a band at
37 kDa in all examined cell lines and an additional band in
Detroit 562 cells at 55 kDa (Fig. 3a). This antibody also
recognized the same bands in the cytoplasm extracts. Based
on the available data [25], only the 37-kDa band can be
considered as specific.
The mouse monoclonal 8 F1 antibody raised against
ERCC1 recognized a band at 37 kDa in Detroit 562 and
Fig. 3 Western blot of FL-297
(a) and 8 F1 (b) anti-ERCC1
antibodies and of SPM228 (d)
anti-XPF antibody in SCC-25
(lane 1) and Detroit 562 (lane 2)
squamous cell carcinoma cell
lines and in not transformed
BEAS-2B bronchial epithelial
cells (lane 3) using cell nuclear
(left panels) and cytoplasm (right
panels) fractions. Ponceau-
stained whole protein detection
was used as loading control (c, e)
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BEAS-2B cells in the cell nuclear extract and did not show
any bands in cytoplasmic extracts (Fig. 3b). The SPM228
mouse monoclonal antibody raised against XPF recognized
the full XPF protein at 116 kDa and its known degradation
derivative [25] in all examined cell lines both in the cell
nuclear and cytoplasm extracts (Fig. 3d). Based on these
results, we assume that the specificity of the 8 F1 antibody
against ERCC1was higher than the one of FL-297, supporting
the results of the immunohistochemical investigations in pa-
tient tissues.
Considering the protein and mRNA expression data, De-
troit 562 and BEAS-2B cells were chosen for further tests,
because they reliably revealed the characteristic 37-kDa
ERCC1 band using several antibodies (Fig. 3a, b). In these
cell lines, ERCC1 expression has been also confirmed at the
mRNA level (not shown). Moreover, for ERCC1 protein
detection, the 8 F1 antibody was considered most suitable,
because it specifically recognized the ERCC1 protein only at
37 kDa, and the reaction products were confined to the nucle-
us (Fig. 3b).
ERCC1 gene expression at IC-50 of CDDP, MMC, and 5-FU
In the next step, we investigated the relation of ERCC1+ and
ERCC1− cells with the outcome of the experimental treatment
with chemotherapeutic drugs. For this purpose, the IC-50
values had to be determined. Using a tetrazolium-based col-
orimetric assay (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenylte-
trazoliumbromide (MTT) assay), the IC-50 (drug concentra-
tion inducing a 50 % growth reduction in comparison to the
control untreated cells) was determined in Detroit 562 and
BEAS-2B cells for CDDP, MMC, and 5-FU. Drug concentra-
tion ranges for the treatment series were based on relevant
publications [32–34, 45]. For Detroit 562 cells, the IC-50
value for CDDP was 4.84 μM, for MMC 0.5 μM, and for 5-
FU 6.32 μM. For BEAS-2B cells, the IC-50 value for CDDP
was 4.87 μM, for MMC 0.43 μM, and for 5-FU 95.08 μM.
After IC-50 treatment with CDDP, the relative protein
levels (whole fluorescence intensity at FL-1 channel in all
events together) increased to 138.08±28.75 % (control
100 %) in Detroit 562 cells and to 115.53±17.01 % in
BEAS-2B cells. After MMC IC-50 treatment, the relative
protein levels changed to 105.89±13.82 % (control 100 %)
in Detroit 562 cells and to 103.98±5.63 % in BEAS-2B cells.
After 5-FU IC-50 treatment, the relative protein levels
changed to 122.49±2.95 % (control 100 %) in Detroit 562
cells and to 91.88±11.61 % in BEAS-2B cells.
For comparison, the ERCC1 gene expression was also
investigated at the mRNA level following the same treatment
conditions. CDDP treatment resulted 2.43 times and 1.43
times upregulation of gene expression (p<0.05) in Detroit
562 and BEAS-2B cells, respectively (control 1.00), whereas
MMC treatment did not influence the ERCC1 mRNA levels
significantly in either Detroit 562 or BEAS-2B cells (p>0.05).
Treatment with 5-FU at IC-50 resulted in a significant
(p<10−4) 2.37 times increase of ERCC1 gene expression in
Detroit 562 cells, while in BEAS-2B cells, the ERCC1 gene
expression tended to decrease (p=0.051) to 80 % (0.8 times)
of the control level.
Cell cycle relation of ERCC1 in control and treated cells
As a possible reason for the favorable response of HNSCC
patients expressing high levels of ERCC1, we hypothesized
that high ERCC1 staining represents particularly radiosensi-
tive cells which are in the G2 phase of the cell cycle [46]. To
test this hypothesis, we established an ERCC1 immunocyto-
chemical analysis combined with propidium iodide DNA
staining in flow cytometry [36, 47]. Then, we used this meth-
od on untreated and IC-50-treated Detroit 562 and BEAS-2B
cells to assess cell cycle dependence of ERCC1 expression
under these conditions.
In untreated Detroit 562 and BEAS-2B cells, the cell cycle
distribution (Table 2) resembled a normal proliferating cell
culture. Cells containing lower DNA content than diploid
(sub-G1 phase) were infrequent. In both cell lines, cells in
the G1 phase occurred most frequently. The cells with DNA
content between diploid and tetraploid were identified as S
phase, and cells with tetraploid DNA content were identified
as G2 (G2/M) phase. S and G2 phases were comparable in
untreated cultures ofDetroit 562 andBEAS-2B cells (Table 2).
After CDDP treatment at IC-50 for 48 h, followed by 1 day
without treatment, Detroit 562 cells accumulated in the S and
G2 phases and the representation of sub-G1 cells had also
increased, which is clearly recognizable in Table 2. The effects
of this treatment on BEAS-2B cells were quite similar. After
MMC treatment at IC-50 for 48 h, followed by 1 day without
Table 2 Cell cycle distribution of Detroit 562 and BEAS-2B cells in
untreated and in IC-50 CDDP-, MMC-, and 5-FU-treated conditions:
mean ± SD, results of five repeats. Not always were all events recognized
in any of the sub-G1, G1, S, or G2 phases, and the percent values do not
necessarily give together 100 %
Untreated CDDP MMC 5-FU
Detroit 562
Sub-G1 5.2±1.9 20.5±8.8 24.1±9.4 19.8±3.2
G1 45.2±5.0 14.5±5.8 13.1±4.6 28.2±6.9
S 20.1±3.3 23.3±3.4 27.6±4.3 23.4±6.0
G2 22.8±4.4 32.0±10.7 28.2±17.8 25.7±1.8
BEAS-2B
Sub-G1 3.2±1.6 22.3±0.7 33.8±5.8 25.1±3.9
G1 42.8±3.9 17.1±1.0 15.0±1.2 14.2±1.5
S 17.0±2.5 20.5±1.3 15.2±2.9 45.9±1.4
G2 26.9±1.3 22.2±3.0 26.9±6.2 7.8±1.7
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treatment, both Detroit 562 and BEAS-2B cells revealed
histograms similar to those after CDDP treatment, with in-
creases of cell numbers in the sub-G1 and increase or mainte-
nance of S and G2 phases (in Table 2, it is more evident for
Detroit 562 cells). The most characteristic is the decrease of
the representation of the G1 phase (Table 2). After 5-FU
treatment at IC-50 concentration for 48 h, followed by 1 day
without treatment, Detroit 562 cells accumulated in the G1-S
phase, and the representation of sub-G1 cells had also in-
creased (Table 2). The 48-h IC-50 (as determined by Detroit
562 cells) 5-FU treatment of BEAS-2B cells followed by
1 day without treatment has led to S phase block (nearly
50 % of all events in the S phase, Table 2), showing this as
the main cell cycle phase, but the representation of sub-G1
cells has also increased (Table 2).
Using the histograms measured in flow cytometry, cells in
the sub-G1, G1, S, and G2 phases were gated and were further
analyzed for fluorescence intensity measured with the
ERCC1-specific immunocytochemical reaction and graphed
on “FL1−fluorescence intensity−relative cell numbers” his-
tograms. The “relative events” (events corresponding to the
ERCC1-related fluorescence levels related to all events at the
same cell cycle phase) were multiplied with the arbitrary
fluorescence units measured at FL1 channel in all cell cycle
phases to get the “cell-cycle-related ERCC1 immunocyto-
chemical values.” As seen in Fig. 4, in untreated and in
CDDP-, MMC-, and 5-FU-treated Detroit 562 (Fig. 4a–d)
and BEAS-2B (Fig. 4e–h) cells, the ERCC1 immunocyto-
chemical values significantly increased from sub-G1, over
G1 and S up to G2/M phases of the cell cycle. This tendency
was observed independently from the chemotherapeutic agent
employed.
CDDP treatment increased the ERCC1-related immunoflu-
orescence levels (from 0.13–0.20 to 0.20–0.30) in both Detroit
562 and BEAS-2B cells (Fig. 4b, f), especially in the G2/M
phase. These data indicate that ERCC1 is most represented in
the radiosensitive G2/M phase, and CDDP, but not MMC,
induces additional ERCC1 expression during treatment.
Hypoxia significantly downregulates ERCC1 in Detroit 562
tumor cells
In a recent publication, Bindra et al. suggested a novel mech-
anism of genetic instability in the tumor microenvironment
mediated by hypoxia-induced suppression of the homologous
recombination pathway in cancer cells [29]. The ERCC1-XPF
a b c d
e f g h
Fig. 4 ERCC1-related fluorescence intensities in Detroit 562 (a–d) and
BEAS-2B (e–h) cells gained with the ERCC1-specific immunocyto-
chemical reaction. The “proportional events” (pe) (events corresponding
to the ERCC1 fluorescence levels related to all events at the same cell
cycle phase) were multiplied with the arbitrary fluorescence units (relative
fluorescence intensity: If) measured at the FL1 channel in all cell cycle
phases to get the “cell-cycle-related ERCC1 immunocytochemical
values” (pe * If). These data represent both the relative distribution of
the cells at cell cycle phases and the ERCC1 staining intensity of the cells
within the cell cycle phases. In fact, the graphs represented show the cell
cycle distribution of ERCC1 protein. Cell cycle-related ERCC1 staining
intensity in untreated (a, e) and CDDP- (b, f), MMC- (c, g), and 5-FU-
treated (d, h) conditions. ***p<0.001
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dimer is a component of the complex machinery in homolo-
gous recombination [3]. We were therefore interested in the
effect of hypoxia on ERCC1 expression.
Detroit 562 cells were cultured in hypoxic and normoxic
conditions for 48–96 h, and ERCC1 mRNA (Fig. 5a) and cell
nuclear protein representation (Fig. 5b) were determined. The
ERCC1 mRNA expression (Fig. 5a) was normalized with β-
actin gene expression and was related to the gene expression
state of the initial 48-h normoxic culture (“control zero”).
Supporting the report of Bindra and coworkers [29], 48–
72 h hypoxic culture conditions led to a significant reduction
of ERCC1 gene expression at mRNA and protein levels
compared to normoxic conditions, even when followed by
24–48 h normoxic periods (Fig. 5a, b).
Discussion
Unexpectedly, 106 HNSCC patients treated with primary
concomitant radiochemotherapy responded better, if ERCC1
expression in pretherapeutic tumor samples was high (Fig. 1).
This finding was mechanistically elusive at the time of obser-
vation, because high ERCC1 expression was considered to
indicate low tumor sensitivity to cross-linking chemothera-
peutic agents such as CDDP [43] or MMC. This outcome
brought us to do some translational experimentation. At first,
the specificity of the 8 F1 ERCC1 mouse monoclonal anti-
body was examined. In immunohistochemical comparisons of
tumor tissues and in western blot experiments in tumor cell
lines (confirmed by RNA results), 8 F1 yielded specific and
plausible results and a relevant bias to low 8 F1 specificity
seemed unlikely.
ERCC1 mediates DNA repair by removing therapeutic
adducts from tumor DNA. Therefore, the positive clinical
effect of high ERCC1 expression in HNSCC patients treated
with primary combined radiochemotherapy was unlikely to be
related to the chemotherapeutic part. We rather assumed some
relation to radiotherapy. It is well known that the effectiveness
of radiotherapy on tumor cells is cell cycle dependent [46]. In
a next step, we thus examined cell cycle dependency of
ERCC1 gene expression. We used an ERCC1-expressing
HNSCC cell line (Detroit 562) and a noncancer airway epi-
thelial cell line (BEAS-2B). With these cell lines, we
established an ERCC1-immunocytochemical analysis com-
bined with propidium iodide DNA staining for flow cytome-
try. Using this setup, we could simultaneously assess ERCC1
protein synthesis and cell cycle phase. Actually, in untreated
cells, ERCC1 expression was the highest in the G2/M phase
(Fig. 4a, e), whose cells are particularly radiosensitive [46].
The association of ERCC1 expression with the radiosensitive
cell cycle phase might in part explain the observed clinical
benefit of high ERCC1 expression. However, in this context,
a
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Fig. 5 Detroit 562 cells were cultured in hypoxic and normoxic condi-
tions for 48–96 h and ERCC1 mRNA expression was examined (a), and
western blot of nuclear ERCC1 protein (b) was performed. The ERCC1
mRNA expression (a) was normalized with β-actin gene expression and
was proportioned to the gene expression of control zero (the gene expres-
sion of the t=0 days, which was the reference for time and treatment-
related changes). “1” represents no change compared to start time (with-
out treatment). The normoxic culture showed no significant fluctuation of
ERCC1 gene expression, while the hypoxic culture (even if followed by
normoxic) resulted in significant ERCC1 gene expression decrease.
Western blot of 8 F1 (b, upper panel) anti-ERCC1 antibody in cell
nuclear extracts of Detroit 562 squamous cell carcinoma cell line cultured
48 h normoxic (1), 48 h hypoxic (2), 72 h normoxic (3), 72 h hypoxic (4),
48 h hypoxic and 24 h normoxic (5), 96 h normoxic (6), and 48 h hypoxic
and 48 h normoxic (7). Ponceau-stained whole protein detection in
nuclear extracts was used as loading control (b, lower panel). Hypoxic
culture conditions, even when followed by normoxic periods, lead to
significant reduction of ERCC1 gene expression at mRNA and protein
levels
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ERCC1 expression is rather an epiphenomenon, while cell
cycle-dependent radiosensitivity is considered an independent
underlying cause. However, it is understood that these results
in two-cell lines are preliminary and rather have a hypothesis
generating than an explanatory character.
The cell cycle relation of ERCC1 function is also discussed
by Nunez et al., who were investigating ERCC1-deficient
hepatocytes and found that a population of cells arrested in
G2 has shown increased DNA content accumulates. This was
associated with a p53-independent accumulation of p21. This
finding also underlines a G2-related ERCC1 function and a
cell-cycle-related ERCC1 expression [4].
We were further interested how chemotherapeutic agents
frequently used in the combined treatment of HNSCC affect
cell cycle distribution and the relation between cell cycle and
ERCC1 expression. To accomplish this, drug concentrations
inducing a 50 % growth reduction in comparison to the
control untreated cells (IC-50) were established for CDDP,
MMC, and 5-FU. The resulting IC-50 values compared well
with known data [32–34]. Both CDDP andMMC treatment at
IC-50 resulted in shifting cells from the less radiosensitive G1
phase to highly radiosensitive G2/M phase [46], and 20–33 %
of cells were detected with fragmented DNA (sub-G1 phase)
indicating apoptosis. In contrast, treatment with 5-FU led to S
phase arrest or G1-S checkpoint arrest. These data comply
with previous studies on radiosensitizing mechanisms of che-
motherapeutic agents [48]. Importantly, CDDP treatment in-
duced a significant increase of ERCC1 gene expression in
tumor and in normal cells, while MMC and 5-FU did not.
However, the relative cell cycle distribution of ERCC1 ex-
pression remained unchanged (Fig. 4a, b, e, f). These data
support previous studies on radiosensitization by chemother-
apeutic agents [48], but again do not provide a mechanistic
basis to suggest an independent effect of ERCC1 on treatment
outcome in HNSCC patients.
Interestingly, hypoxia reduced ERCC1 gene expression
(both at the mRNA and protein levels) and even post-
hypoxic, normoxic periods did not recover these changes. In
fact, hypoxic cells are up to threefold more resistant to ioniz-
ing radiation than cells irradiated under well-oxygenated con-
ditions [49]. Hypoxia appears to be a key microenvironmental
factor involved in the development of genetic instability [29],
and it also reduces the efficiency of radiation therapy. Bindra
et al. reported that mediators of homologous recombination
are downregulated by hypoxia [29]. In accordance, our exper-
imental findings in Detroit 562 HNSCC tumor cells also
showed that ERCC1 gene expression at the mRNA and pro-
tein levels decreased under hypoxia, and even a subsequent
normoxic condition did not recover the gene expression
changes. Indirectly, it could be assumed that nuclear
ERCC1-positive cells in pretreatment biopsy samples might
indicate normoxic cells, which are genetically stable, and
more radiosensitive than hypoxic cells.
In addition, a recent study highlights that ERCC1 gene
expression and protein level does not directly mean function-
ality. Martens-de Kemp and coworkers from the laboratory of
Dr. Brakenhoff recently published that the CDDP-DNA ad-
duct level is the most important determinant of cisplatin
sensitivity in HNSCC cells, which does not correlate with
the gene expression of ERCC1 [50]. These data doubt the
direct predictive value of the gene expression level of ERCC1
in pretherapeutic biopsies for the level of CDDP-induced
DNA damage and cisplatin effectiveness. Indeed, by
immunostaining, we are recognizing gene expression
and protein synthesis, which reflect regulatory conditions
in the tumor tissue, and the ERCC1 level is an indicator
of these conditions. The protein function is less mirrored
by immunostaining. The current study suggests that
ERCC1 staining with mouse monoclonal antibody is an
indicator of favorable cell cycle distribution and normoxic
conditions.
The current study has several limitations. We analyzed
early CR as a marker to treatment response. Identifying early
treatment failure moves closer to treatment decision than
survival analysis after years. In truth, the follow-up period
was rather short in this patient collective for comprehensive
survival analysis. Nevertheless, according to Michiels et al.
loco-regional control is considered as an effective surro-
gate endpoint marker [51]. A second limitation is that
oropharyngeal carcinomas were overrepresented. Accord-
ingly, Patel et al. have recently published that patients
with oropharyngeal HNSCC and high ERCC1 expression
were more likely to survive and remain disease-free when
compared to nonoropharyngeal squamous cell carcinoma
patients with high ERCC1 expression despite treatment
modality and human papillomavirus virus (HPV) status
[52].
Conclusion
The results of these investigations suggest that ERCC1 has no
predictive value for or against radiochemotherapy in HNSCC
on its own, but is an indicator of well-known tumor cell factors
as radiosensitive cell cycle phase and normoxic condition,
which influence treatment outcome.
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